These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17552518)

  • 1. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
    Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
    J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.
    Kozikowski AP; Gunosewoyo H; Guo S; Gaisina IN; Walter RL; Ketcherside A; McClung CA; Mesecar AD; Caldarone B
    ChemMedChem; 2011 Sep; 6(9):1593-602. PubMed ID: 21732538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.
    Li X; Bijur GN; Jope RS
    Bipolar Disord; 2002 Apr; 4(2):137-44. PubMed ID: 12071511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
    Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
    Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
    Rybakowski JK
    CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
    Azab AN; Vainer E; Agam G; Bersudsky Y
    J Clin Psychopharmacol; 2017 Apr; 37(2):226-230. PubMed ID: 28106616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
    Pandey GN; Ren X; Rizavi HS; Dwivedi Y
    J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons.
    Hall AC; Brennan A; Goold RG; Cleverley K; Lucas FR; Gordon-Weeks PR; Salinas PC
    Mol Cell Neurosci; 2002 Jun; 20(2):257-70. PubMed ID: 12093158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta.
    Silva R; Mesquita AR; Bessa J; Sousa JC; Sotiropoulos I; Leão P; Almeida OF; Sousa N
    Neuroscience; 2008 Mar; 152(3):656-69. PubMed ID: 18291594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
    Chen G; Huang LD; Jiang YM; Manji HK
    J Neurochem; 1999 Mar; 72(3):1327-30. PubMed ID: 10037507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between lithium sensitivity and GSK3beta gene polymorphisms in bipolar disorder].
    Numajiri M; Aoki J; Iwahashi K; Fukamauchi F; Enomoto M; Yoshihara E; Murayama O; Nishizawa D; Ikeda K; Ishigooka J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Jun; 32(3):161-3. PubMed ID: 22834106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
    Furlotti G; Alisi MA; Cazzolla N; Dragone P; Durando L; Magarò G; Mancini F; Mangano G; Ombrato R; Vitiello M; Armirotti A; Capurro V; Lanfranco M; Ottonello G; Summa M; Reggiani A
    J Med Chem; 2015 Nov; 58(22):8920-37. PubMed ID: 26486317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Wnt signaling pathway in bipolar disorder.
    Gould TD; Manji HK
    Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
    Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
    Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium.
    Lin YF; Huang MC; Liu HC
    J Affect Disord; 2013 May; 147(1-3):401-6. PubMed ID: 23021822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors.
    Gould TD; Einat H; O'Donnell KC; Picchini AM; Schloesser RJ; Manji HK
    Neuropsychopharmacology; 2007 Oct; 32(10):2173-83. PubMed ID: 17299510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors.
    Du J; Wei Y; Liu L; Wang Y; Khairova R; Blumenthal R; Tragon T; Hunsberger JG; Machado-Vieira R; Drevets W; Wang YT; Manji HK
    Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11573-8. PubMed ID: 20534517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.